(thirdQuint)Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg.

 To assess the single dose pharmacokinetics, safety, and tolerability of GLA5PR GLARS-NF3 tablet 150mg administered regular die relative to GLA5PR GLARS-NF1 tablet 150mg administered regular diet.

 IP will be administered 1 tablet(150mg) once a day(QD) after evening meal.

.

 Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg@highlight

The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR GLARS-NF3 tablet 150mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 150mg administered regular diet and (2) determine the safety and tolerability of a single dose of GLA5PR GLARS-NF3 tablet 150mg administered regular diet and GLA5PR GLARS-NF1 tablet 150mg administered regular diet.

